Bicycle Therapeutics (BCYC) Operating Margin (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Operating Margin came in at 8673.93% in Q2 2026, down 570810.0% YoY from N/an in Q2 2025, and down 17.49% on a QoQ basis from 7382.41% in Q1 2026.
Bicycle Therapeutics (BCYC) Operating Margin (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of Operating Margin data on file, last reported at 8673.93% in Q2 2026.
- Quarterly Operating Margin fell 570810.0% year-over-year to 8673.93% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 343.6% (up 115173.0% YoY) and the FY2025 annual result came in at 340.38%, up 25458.0% from the prior year.
- Operating Margin eased to 8673.93% in Q2 2026, from 7382.41% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 51.52% in Q4 2025 to a low of 8673.93% in Q2 2026.
- A 5-year average of 1719.18% and a median of 781.61% in 2023 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2025 — Operating Margin jumped 182723 bps — and 2026, when it plunged 667875 bps.
- Tracing BCYC's Operating Margin over 5 years: stood at 383.46% in 2022, then slumped by 165 bps to 1017.35% in 2023, then plunged by 79 bps to 1824.78% in 2024, then surged by 97 bps to 51.52% in 2025, then slumped by 16735 bps to 8673.93% in 2026.
- The last three Operating Margin figures came in at 8673.93% (Q2 2026), 7382.41% (Q1 2026), and 51.52% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | -8,673.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8,673.93% |
| Mar 31, 2026 | -7,382.41% |
| Dec 31, 2025 | -51.52% |
| Sep 30, 2025 | -558.64% |
| Jun 30, 2025 | -2,965.82% |
| Mar 31, 2025 | -703.66% |
| Dec 31, 2024 | -1,824.78% |
| Sep 30, 2024 | -2,385.87% |
| Jun 30, 2024 | -498.31% |
| Mar 31, 2024 | -304.96% |
| Dec 31, 2023 | -1,017.35% |
| Sep 30, 2023 | -949.12% |
| Jun 30, 2023 | -378.27% |
| Mar 31, 2023 | -853.82% |
| Dec 31, 2022 | -383.46% |
| Sep 30, 2022 | -978.91% |
| Jun 30, 2022 | -515.09% |
| Mar 31, 2022 | -709.40% |
| Dec 31, 2021 | -1,126.50% |
| Sep 30, 2021 | -329.89% |